MindMed Completes Enrollment Of Phase 2b Trial Of MM-120 In Generalized Anxiety Disorder (GAD)
Portfolio Pulse from Bill Haddad
MindMed has completed the enrollment for its Phase 2b trial of MM-120, a drug aimed at treating Generalized Anxiety Disorder (GAD).
September 12, 2023 | 11:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MindMed's completion of enrollment for its Phase 2b trial of MM-120 could potentially lead to positive outcomes for the company if the trial results are successful.
The completion of enrollment for the Phase 2b trial of MM-120 indicates progress in MindMed's drug development process. If the trial results are successful, it could potentially lead to regulatory approval and commercialization of the drug, which would positively impact the company's revenues and stock price.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100